WebGenus Oncology LLC 227 WEST MONROE STREET CHICAGO, IL 60606 United States DUNS: 803604334 HUBZone Owned: No Woman Owned: No Socially and Economically Disadvantaged: No Principal Investigator Phone: () - Business Contact Phone: (312) 425-3631 Research Institution N/A Abstract WebJun 21, 2024 · 1 Genus Oncology, Boston, Massachusetts, USA. 2 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. 3 Departments of …
Taxonomy Code 207RH0003X - Internal Medicine Hematology & Oncology
WebFor the past 18 years, Rick has actively participated in funding cancer research in the United States, as well as in Europe and Japan. He serves as the Chairman of Genus Oncology, a research partnership with … WebFeb 16, 2011 · VERNON HILLS, Ill., Feb. 15, 2011 /PRNewswire/ -- Genus Oncology, LLC, a clinical-stage company focused on commercializing novel drugs for treatment of cancer, announced it has successfully filed an Investigational New Drug (IND) application with the US Food & Drug Administration (FDA) and has dosed the first patient in a Phase I trial to … csernyin rita
Genus Oncology, LLC Announces Initiation of Phase I Trial of GO …
Websubdivision. subfamily. variety. See also synonyms for: genera. On this page you'll find 32 synonyms, antonyms, and words related to genus, such as: brand, breed, category, … WebJun 21, 2024 · 1 Genus Oncology, Boston, Massachusetts, USA. 2 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. 3 Departments of Medicine and Pathology, Boston University School ... WebJan 18, 2016 · The purpose of this research study is to test the safety of GO-203-2C with bortezomib. GO-203-2C is a newly discovered compound that binds to an oncoprotein (a cancer causing protein) called MUC1. Myeloma cells harbor an increased amount of MUC1 on its cell surface. By binding to MUC1, GO-203-2C has been shown to cause tumor cell … csernus podcast